Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Oligo (dT) 25 Beads: Optimizing Superparamagnetic mRNA Isola
2026-06-11
Oligo (dT) 25 Beads enable rapid, high-yield eukaryotic mRNA isolation with unmatched specificity and direct compatibility with sensitive downstream applications. This guide details experimental workflows, troubleshooting strategies, and translational insights to maximize performance in advanced gene expression studies.
-
TPCA-1: Selective IKK-2 Inhibitor for NF-κB Pathway Research
2026-06-10
TPCA-1 is a potent, selective IKK-2 inhibitor used to dissect NF-κB-mediated inflammation. It demonstrates high selectivity, robust cytokine inhibition, and proven in vivo efficacy in arthritis models.
-
Scenario-Driven Insights with MCL-1 Inhibitor A-1210477 (SKU
2026-06-10
This article offers an evidence-based, scenario-driven guide for using MCL-1 inhibitor A-1210477 (SKU B6011) to resolve common workflow and interpretation challenges in apoptosis assays. With practical Q&A, validated protocol parameters, and candid vendor selection advice, researchers can optimize their cancer cell viability studies and ensure data reliability with APExBIO’s A-1210477.
-
PA-824: Bicyclic Nitroimidazole for Drug-Resistant Tuberculo
2026-06-09
PA-824 stands out as a potent bicyclic nitroimidazole derivative for tackling both drug-sensitive and resistant Mycobacterium tuberculosis, enabling robust and reproducible research in challenging TB models. Its dual-action mechanism, DMSO solubility, and high purity make it an essential tool for advanced tuberculosis research and experimental drug development.
-
ApoEVs Drive LUAD Metastasis via SOX2 and ALDH1A1 Signaling
2026-06-09
This study uncovers how apoptotic extracellular vesicles (apoEVs) from tumor cells promote metastasis and stemness in lung adenocarcinoma (LUAD) by activating SOX2 transcription and the NF-κB pathway via ALDH1A1 transfer. These findings reveal a new mechanism of tumor cell communication, highlighting apoEVs-ALDH1A1 as a potential therapeutic target for LUAD recurrence.
-
KG-501 (SKU B8380): Reliable CREB Inhibition for Cell Assays
2026-06-08
This article provides a scenario-driven guide to deploying KG-501 (SKU B8380) as a robust transcriptional coactivator disruptor in cell viability and proliferation assays. Drawing from peer-reviewed evidence and practical laboratory challenges, it emphasizes reproducibility, protocol optimization, and vendor reliability for biomedical researchers and technicians.
-
AZD0156: ATM Kinase Inhibitor Workflows for Cancer Therapy R
2026-06-08
AZD0156 stands out as a highly selective ATM kinase inhibitor, empowering cancer therapy research through precise DNA damage response modulation. This guide demystifies AZD0156’s use in combinatorial assays, metabolic vulnerability exploration, and offers actionable troubleshooting for experimental success.
-
Protease Inhibitor Cocktails: Strategic Protection for Trans
2026-06-07
This article explores the mechanistic and strategic imperatives of using EDTA-free protease inhibitor cocktails in translational research. By integrating mechanistic insight with workflow guidance, it addresses the preservation of protein integrity in phosphorylation-sensitive and complex biochemical applications. Drawing on recent literature and product innovations, it provides actionable recommendations for researchers aiming to maximize fidelity in protein extraction, immunoassays, and post-translational modification analyses.
-
Mapping Nucleosome Distortion in Chromatin with Single-Molec
2026-06-06
The referenced study introduces the IDLI computational method, enabling unprecedented mapping of nucleosome structural heterogeneity and distortion at single-molecule resolution across chromatin fibers. These findings reshape our understanding of transcription factor interactions, nucleosome remodeling, and their roles in cell-type-specific gene regulation.
-
KR-12 Peptide Engineering: Advances for Antimicrobial Resist
2026-06-05
The reference study reviews the rational design and functional expansion of KR-12, a small human-derived antimicrobial peptide, and its derivatives. By engineering structure and delivery, these peptides demonstrate enhanced efficacy against drug-resistant pathogens and biofilms, highlighting their potential in antibiotic resistance research and therapeutic development.
-
TECPR1-Driven Lysosomal Repair During Energy Stress: Mechani
2026-06-05
This study uncovers a new mechanism for lysosomal membrane repair during energy crisis, identifying TECPR1 as a key mediator that orchestrates membrane tubulation and restoration. These findings deepen our understanding of cellular adaptation to metabolic stress and provide a foundation for future research into lysosome-related metabolic disorders.
-
Phosbind Acrylamide: Phosphate-Binding Reagent for Precision
2026-06-04
Phosbind Acrylamide enables direct, antibody-free detection of protein phosphorylation states by SDS-PAGE, streamlining workflows in signal transduction research. This guide details practical protocols, troubleshooting strategies, and experimental insights, empowering users to achieve high-resolution, reproducible results in protein phosphorylation analysis.
-
IR-1061: Engineering Superior NIR Fluorescent Probes for Dee
2026-06-04
Explore the advanced design and optimization of IR-1061, a near infrared fluorescent dye, for deep-tissue in vivo imaging. This article uniquely analyzes matrix engineering and polarity matching, delivering actionable insights for next-generation biomedical imaging workflows.
-
MDV3100 (Enzalutamide): Mechanisms and Benchmarks in Prostat
2026-06-03
MDV3100 (Enzalutamide) is a second-generation androgen receptor antagonist that disrupts androgen receptor function in prostate cancer cells, particularly in castration-resistant disease. It inhibits AR nuclear translocation, blocks DNA binding, and induces apoptosis in AR-amplified tumors. Recent studies reveal glycosylation pathways can influence resistance to MDV3100, highlighting the complexity of AR pathway modulation.
-
ECL Chemiluminescent Substrate Detection Kit: Optimizing HRP
2026-06-03
The ECL Chemiluminescent Substrate Detection Kit (Hypersensitive) empowers researchers to achieve ultrasensitive, low-background detection of scarce proteins on nitrocellulose and PVDF membranes. Its robust signal duration and cost-effective antibody usage streamline advanced immunoblotting workflows, even in challenging cancer microenvironment studies.
8629 records 11/576 page Previous Next First page 上5页 1112131415 下5页 Last page